Investor Expectations to Drive Momentum within

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2022
42
Investor Expectations to Drive Momentum within Anheuser-Busch InBev SA/NV, Monmouth Real Estate Investment, Superior Energy Services, EPAM, Airgain, and Vera Bradley — Discovering Underlying Factors of Influence

NEW YORK, Feb. 11, 2019 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of Anheuser-Busch InBev SA/NV (NYSE: BUD ), Monmouth Real Estate Investment Corporation (NYSE: MNR ), Superior Energy Services, Inc. (NYSE: SPN ), EPAM Systems, Inc. (NYSE: EPAM ), Airgain, Inc. (NASDAQ: AIRG ), and Vera Bradley, Inc. (NASDAQ: VRA ), including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research.

Complimentary Access: Research Reports

Full copies of recently published reports are available to readers at the links below.

BUD DOWNLOAD: http://Capital-Review.com/register/?so=BUD MNR DOWNLOAD: http://Capital-Review.com/register/?so=MNR SPN DOWNLOAD: http://Capital-Review.com/register/?so=SPN EPAM DOWNLOAD: http://Capital-Review.com/register/?so=EPAM AIRG DOWNLOAD: http://Capital-Review.com/register/?so=AIRG VRA DOWNLOAD: http://Capital-Review.com/register/?so=VRA

(You may have to copy and paste the link into your browser and hit the [ENTER] key)

The new research reports from Capital Review, available for free download at the links above, examine Anheuser-Busch InBev SA/NV (NYSE: BUD ), Monmouth Real Estate Investment Corporation (NYSE: MNR ), Superior Energy Services, Inc. (NYSE: SPN ), EPAM Systems, Inc. (NYSE: EPAM ), Airgain, Inc. (NASDAQ: AIRG ), and Vera Bradley, Inc. (NASDAQ: VRA ) on a fundamental level and outlines the overall demand for their products and services in addition to an in-depth review of the business strategy, management discussion, and overall direction going forward. Several excerpts from the recently released reports are available to today's readers below.

-----------------------------------------

Important Notice: the following excerpts are not designed to be standalone summaries and as such, important information may be missing from these samples. Please download the entire research report, free of charge, to ensure you are reading all relevant material information. All information in this release was accessed February 7th, 2019. Percentage calculations are performed after rounding. All amounts in millions (MM), except per share amounts.

-----------------------------------------

ANHEUSER-BUSCH INBEV SA/NV (BUD) REPORT OVERVIEW

Anheuser-Busch InBev SA/NV's Recent Financial Performance

For the three months ended September 30th, 2018 vs September 30th, 2017, Anheuser-Busch InBev SA/NV reported revenue of $13,282.00MM vs $14,740.00MM (down 9.89%) and analysts estimated basic earnings per share $0.48 vs $1.04 (down 53.85%). For the twelve months ended December 31st, 2017 vs December 31st, 2016, Anheuser-Busch InBev SA/NV reported revenue of $56,444.00MM vs $45,517.00MM (up 24.01%) and analysts estimated basic earnings per share $4.06 vs $0.72 (up 463.89%). Analysts expect earnings to be released on February 28th, 2019. The report will be for the fiscal period ending December 31st, 2018. The reported EPS for the same quarter last year was $1.04. The estimated EPS forecast for the next fiscal year is $4.44 and is expected to report on February 28th, 2019.

To read the full Anheuser-Busch InBev SA/NV (BUD) report, download it here: http://Capital-Review.com/register/?so=BUD

-----------------------------------------

MONMOUTH REAL ESTATE INVESTMENT CORPORATION (MNR) REPORT OVERVIEW

Monmouth Real Estate Investment's Recent Financial Performance

For the three months ended September 30th, 2018 vs September 30th, 2017, Monmouth Real Estate Investment reported revenue of $36.60MM vs $33.29MM (up 9.96%) and analysts estimated basic earnings per share $0.09 vs $0.09 (unchanged). For the twelve months ended September 30th, 2018 vs September 30th, 2017, Monmouth Real Estate Investment reported revenue of $139.37MM vs $116.39MM (up 19.75%) and analysts estimated basic earnings per share $0.49 vs $0.32 (up 53.13%). Analysts expect earnings to be released on May 14th, 2019. The report will be for the fiscal period ending March 31st, 2019. Reported EPS for the same quarter last year was $0.22. The estimated EPS forecast for the next fiscal year is $1.14 and is expected to report on November 27th, 2019.

To read the full Monmouth Real Estate Investment Corporation (MNR) report, download it here: http://Capital-Review.com/register/?so=MNR

-----------------------------------------

SUPERIOR ENERGY SERVICES, INC. (SPN) REPORT OVERVIEW

Superior Energy Services' Recent Financial Performance

For the three months ended September 30th, 2018 vs September 30th, 2017, Superior Energy Services reported revenue of $573.07MM vs $506.03MM (up 13.25%) and analysts estimated basic earnings per share -$0.14 vs -$0.39. For the twelve months ended December 31st, 2017 vs December 31st, 2016, Superior Energy Services reported revenue of $1,874.08MM vs $1,450.05MM (up 29.24%) and analysts estimated basic earnings per share -$1.35 vs -$5.85. Analysts expect earnings to be released on February 18th, 2019. The report will be for the fiscal period ending December 31st, 2018. Reported EPS for the same quarter last year was -$0.33. The estimated EPS forecast for the next fiscal year is -$0.95 and is expected to report on February 18th, 2019.

To read the full Superior Energy Services, Inc. (SPN) report, download it here: http://Capital-Review.com/register/?so=SPN

-----------------------------------------

EPAM SYSTEMS, INC. (EPAM) REPORT OVERVIEW

EPAM's Recent Financial Performance

For the three months ended September 30th, 2018 vs September 30th, 2017, EPAM reported revenue of $468.19MM vs $377.52MM (up 24.02%) and basic earnings per share $1.22 vs $0.81 (up 50.62%). For the twelve months ended December 31st, 2017 vs December 31st, 2016, EPAM reported revenue of $1,450.45MM vs $1,160.13MM (up 25.02%) and analysts estimated basic earnings per share $1.40 vs $1.97 (down 28.93%). Analysts expect earnings to be released on February 14th, 2019. The report will be for the fiscal period ending December 31st, 2018. The reported EPS for the same quarter last year was $0.83. The estimated EPS forecast for the next fiscal year is $4.18 and is expected to report on February 14th, 2019.

To read the full EPAM Systems, Inc. (EPAM) report, download it here: http://Capital-Review.com/register/?so=EPAM

-----------------------------------------

AIRGAIN, INC. (AIRG) REPORT OVERVIEW

Airgain's Recent Financial Performance

For the three months ended September 30th, 2018 vs September 30th, 2017, Airgain reported revenue of $15.79MM vs $12.45MM (up 26.82%) and analysts estimated basic earnings per share $0.05 vs $0.02 (up 150.00%). For the twelve months ended December 31st, 2017 vs December 31st, 2016, Airgain reported revenue of $49.52MM vs $43.43MM (up 14.02%) and analysts estimated basic earnings per share $0.12 vs $0.65 (down 81.54%). Analysts expect earnings to be released on February 14th, 2019. The report will be for the fiscal period ending December 31st, 2018. The reported EPS for the same quarter last year was $0.06. The estimated EPS forecast for the next fiscal year is $0.04 and is expected to report on February 14th, 2019.

To read the full Airgain, Inc. (AIRG) report, download it here: http://Capital-Review.com/register/?so=AIRG

-----------------------------------------

VERA BRADLEY, INC. (VRA) REPORT OVERVIEW

Vera Bradley's Recent Financial Performance

For the three months ended October 31st, 2018 vs October 31st, 2017, Vera Bradley reported revenue of $97.69MM vs $114.10MM (down 14.38%) and analysts estimated basic earnings per share $0.12 vs $0.01 (up 1,100.00%). For the twelve months ended January 31st, 2018 vs January 31st, 2017, Vera Bradley reported revenue of $454.65MM vs $485.94MM (down 6.44%) and analysts estimated basic earnings per share $0.20 vs $0.54 (down 62.96%). Analysts expect earnings to be released on March 13th, 2019. The report will be for the fiscal period ending January 31st, 2019. The reported EPS for the same quarter last year was $0.33. The estimated EPS forecast for the next fiscal year is $0.63 and is expected to report on March 13th, 2019.

To read the full Vera Bradley, Inc. (VRA) report, download it here: http://Capital-Review.com/register/?so=VRA

-----------------------------------------

ABOUT CAPITAL REVIEW

Capital Review is a nationally recognized publisher of financial analysis, research reports, and exclusive market reporting. Institutional investors, registered brokers, professional traders, and personal investment advisers rely on Capital Review to quantify public company valuations, discover opportunity across asset classes, stay informed about market-moving events, and read exclusive analysis of important material developments. With 14 offices worldwide, Capital Review staffs and manages certified and registered financial professionals, including Chartered Financial Analyst® (CFA®) designation holders and FINRA® BrokerCheck® certified individuals with current and valid CRD® number designations, to enable continuous coverage of topics relevant to its regular active reader base.

REGISTERED MEMBER STATUS

Capital Review's oversight and audit staff are registered analysts, brokers, and/or financial advisers ("Registered Members") working within Equity Research, Media, and Compliance departments. Capital Review's roster includes qualified CFA® charterholders, licensed securities attorneys, and registered FINRA® members holding duly issued CRD® numbers. Current licensed status of several Registered Members at Capital Review have been independently verified by an outside audit firm, including policy and audit records duly executed by Registered Members. Complaints, concerns, questions, or inquiries regarding this release should be directed to Capital Review's Compliance department by Phone, at +1 (410) 280-7496, or by E-mail at compliance@Capital-Review.com.

LEGAL NOTICES

Information contained herein is not an offer or solicitation to buy, hold, or sell any security. Capital Review, Capital Review members, and/or Capital Review affiliates are not responsible for any gains or losses that result from the opinions expressed. Capital Review makes no representations as to the completeness, accuracy, or timeliness of the material provided and all materials are subject to change without notice. Capital Review has not been compensated for the publication of this press release by any of the above mentioned companies. Capital Review is not a financial advisory firm, investment adviser, or broker-dealer, and does not undertake any activities that would require such registration. For our full disclaimer, disclosure, and terms of service please visit our website.

Media Contact: Nicole Garrens, Media Department Office: +1 (410) 280-7496 E-mail: media@Capital-Review.com

© 2019 Capital Review. All Rights Reserved. For republishing permissions, please contact a partner network manager at partnership@Capital-Review.com.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

FINRA®, BrokerCheck®, and CRD® are registered trademarks owned by Financial Industry Regulatory Authority, Inc.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Cleaner Air in Bedroom May Stabilize Blood Sugar Levels

Updated Category News Views 354

Imagine a world where simply sleeping in cleaner air could affect your blood sugar. Seems far-fetched, I know. But that's where we're at with this new study out of NYU Langone Health. They're talking about using plain ol' portable air filters to help steady blood sugar levels for folks dealing with prediabetes. Turns out a cleaner bedroom might just hold the key to taming...

Continue Reading
Antengene’s AnTenGager-D2 Advances in Cancer Treatment

Updated Category News Views 86

Antengene's AnTenGager-D2 Offers Fresh Hope Alright, let's dig into the latest buzz from the 2026 Society for Immunotherapy of Cancer conference about Antengene's AnTenGager-D2 platform. If you're not into biotech lingo, buckle up, because this is a ride into the future of cancer treatments—where science fiction might soon become science fact. A Novel Approach to Tumor...

Continue Reading
Innovent's SINTBILO® Hits Primary Endpoint in Study

Updated Category News Views 146

Innovent's Latest Breakthrough with SINTBILO® One moment you're sipping coffee, the next you're staring at a clinical milestone. Innovent Biologics has shouted from the rooftops that their drug, SINTBILO® (tafolecimab injection), has wrapped up its Phase 3 CREDIT-5 study, snagging the primary endpoint with both hands. This isn't just any drug; it's marked as the first...

Continue Reading
Intelligent Communication Forum Eyes Global Ecosystem Shift

Updated Category News Views 627

China's Grand Vision for Intelligent Communication You know what they say about big ideas—they start in the most bustling of places. And here we are in Wuxi, a city's pulse pounding with ambition, hosting the 2026 China International Intelligent Communication Forum. Picture it: From November 8th to 10th, movers, shakers, and visionaries are scribbling new blueprints for...

Continue Reading
Fibocom Unveils U6G Solutions Advancing Global 5G Tech

Updated Category News Views 26

Breaking Barriers with U6G-Capable Technology Sneaking into the industry's spotlight at MWC Doha 2026, Fibocom flaunts a robust lineup of next-gen 5G solutions. It's as if they're shuffling every card they’ve got to win over the broadband world. With breakthroughs like the FG390, FG370, and FG670 modules, alongside PCBA-level innovations, Fibocom is not just throwing...

Continue Reading
LG's ASIL D Certification: A Game Changer in Autos

Updated Category News Views 129

Why LG's ASIL D Certification Matters There ain't much in the tangled mess of automotive innovations these days that'll make a seasoned investor raise an eyebrow, but here comes LG Electronics grabbing the ASIL D certification like it's a badge of market honor. The ISO 26262 ASIL D is no walk in the park, folks—it's the top rung on the safety ladder, something that's...

Continue Reading
Fibocom LTE Modules Test Drive Satellite Connectivity

Updated Category News Views 153

Boosting IoT with Satellite Connectivity Here's a good one for folks watching the edge of wireless innovation. Fibocom's LTE Cat.1 bis modules, the LE270-EU and LE271-GL, just stretched their legs in New Zealand, connecting seamlessly with SpaceX's Direct to Cell (DTC) satellite system. No fancy hardware swaps, just standard firmware strutting its stuff across satellite...

Continue Reading
Wuliangye Aims for Global Branding Boost at Panda Event

Updated Category News Views 27

Wuliangye Takes Center Stage at Global Event Everyone's chasing that global branding magic, but here's Wuliangye strutting its stuff at the Global Panda Partners Conference. Held in Sichuan Province from November 2 to 4, this is not just another show; it's a bold move from the Chinese baijiu maker to push the 'harmony and coexistence' mantra on the world stage. Not just...

Continue Reading
ASMAX Unleashes Next-Level Motorcycle Comms at EICMA

Updated Category News Views 50

Transforming the Motorcycle Communication Landscape Motorcycling ain't just about the roaring engines and the rubber on the road. In the world of helmets and handlebars, some bright minds are weaving tech magic at the EICMA 2026 in Milan. ASMAX has rolled out its shiny new RoamX intercom gadget, leaving folks buzzing at Hall 6. What RoamX Brings to the Table This ain't...

Continue Reading
JNJ's Dual-Antigen Therapy Shows Promise in Prostate Cancer

Updated Category News Views 294

Exploring a New Front in Cancer Treatment Johnson & Johnson (NYSE: JNJ) just dropped a bombshell at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, unveiling data that could reshape prostate cancer care. Their pioneering combo of pasritamig and JNJ-9401, a dual-antigen-targeted therapy, has the scientific community buzzing. Yeah, it's just Phase 1 baby...

Continue Reading

Top 5 Most Recently Viewed Articles

Iceland Seafood International hf Announces Successful Bill Auction

Updated Category News Views 171

Iceland Seafood International hf's Successful Auction Iceland Seafood International hf. has recently completed an offering of 3-month bills under the new series ICESEA 25 0304. This significant milestone reflects the company's ongoing efforts to strengthen its financial position and enhance its market presence. Details of the Bill Auction The total offers for the bills...

Continue Reading
Prolong Pharmaceuticals Showcases PP-007 in Innovative Stroke Study

Updated Category News Views 194

Prolong Pharmaceuticals Highlights Phase 1 Results for Acute Ischemic Stroke Treatment Prolong Pharmaceuticals, LLC, a clinical-stage biopharmaceutical firm, is making waves in the medical community with its recent announcement regarding the preliminary data from the HEMERA-1 trial. This significant study looks into the effects of their lead asset, PP-007, in treating...

Continue Reading
Investors Urged to Join Class Action Against Verve Therapeutics

Updated Category News Views 89

Investors: Consider Joining the Verve Therapeutics Class Action Robbins LLP, a shareholder-rights law firm, is reminding investors about an important window to act in the class action against Verve Therapeutics, Inc. (NASDAQ: VERV). The lawsuit covers individuals and entities that bought or otherwise acquired Verve securities during a defined time frame. Verve is a...

Continue Reading
Top Dividend Stocks for Passive Income Success

Updated Category News Views 246

Building Passive Income Through Smart Investments Creating passive income is a crucial element of a successful early retirement plan. Establishing various sources of passive income is important to reduce the pressure of depending solely on active work for financial support. A key aspect of this strategy is investing in companies known for their above-average dividends,...

Continue Reading
Temperature Monitoring Devices Market Expected to Surge

Updated Category News Views 61

The temperature monitoring devices market experienced a notable surge back in 2024, with projections estimating a compound annual growth rate (CAGR) of 4.5% through to 2034. By the end of that forecast period, sales revenue was set to hit around USD 5.3 billion—a clear indicator of robust expansion in this critical sector. Market Dynamics: Diverse Applications Across...

Continue Reading